

Aspects of PV

Time	Question
00:42	As experienced clinicians that developed the symptom scoring system, how do you approach this issue?
02:34	How do you use these scoring systems or do you not when you see a patient in consultation?
04:21	Assessing hypercoagulability in the myeloproliferative diseases – Would you think that this should be part of the routine work-up of a patient?
09:00	How do you decide on which drug to use? What's your evaluation of the new agents as of 2015?
15:10	What are some of the unmet needs that we still need to accomplish as our goals in the myeloproliferative diseases?
17:12	Do you think gene sequencing or JAK2 levels both are useful for diagnosis and evaluating the patient?